Our Values

Christina Chan, Senior Vice President, Corporate Communications and Citizenship: Integrity and corporate responsibility are so ingrained in Regeneron. Can you talk a little bit from your perspective, what it means to you and how you've seen it even evolve?

Beth F. Holly, Senior Vice President, Associate General Counsel and Chief Compliance Officer: I've been with this company for almost 14 years, but throughout all of that is this kind of consistent thread of always taking the high road, of choosing to be proud, not just of our results, but of how we got there. Doing it the right way is part of how we operate. It's really essential because we're creating products that people are taking into their bodies and they are trusting us. And for them to trust us, they have to trust what they hear from us.

Christina: Yeah, and I think that coming in, I joined the company at the end of last year. People here really live by it. I think it's in the small decisions people are making, but also the large ones. What are the right choices to make, not just for programs, but for our patients and all of our stakeholders?

Beth: We can only do well by our patients. We can only do well by our shareholders, by our stakeholders, by regulators. If we are always thinking about how are we doing this right? Are we doing it the right way? Are we doing it for the right reasons? The reason that doing well by doing good is such a powerful mantra for this company is that it really doesn't matter what aspect of the business you're engaged in.

Christina: When we look at our overarching corporate responsibility focus areas, we're really looking at improving the lives of people with serious diseases, building a culture of integrity and excellence, which we've talked a lot about and building sustainable communities. One of the things for Regeneron that's been so impressive to see is our commitment to STEM education. Over 90% of our philanthropic contributions actually go to STEM initiatives. So, it's not just about finding and supporting certain students. It's about building that love of science for everyone. How can we build that interest? How do we help teachers find students who have this love and nurture it? And I think that's one of the areas that is of great interest for Regeneron and a place that we can really make a big impact.

Beth: Regeneron's commitment to philanthropy really flows down to the employee level. And we have a remarkable level of employee volunteerism. We have the Regeneron Day for Doing Good and people throughout the company are putting their own sweat equity and their own hours and their own ingenuity into helping support these broader philanthropic goals.

Christina: When I started in October, one of the great things that I got to do was actually be here for the fifth annual Day for Doing Good. And it was such a great introduction to the people of Regeneron. And this year, what I found out is that over 4,000 of our employees dedicated over 14,000 volunteer hours for Day for Doing Good. And Regeneron really has the spirit of wanting to give back, wanting to build our communities to be stronger. When we've set 2025 goals, what we're looking at is setting things that are aggressive. They focus on areas of sustainability, environmental sustainability. They're really looking at how we can help patients with access. We're also looking at ways to help increase the STEM pipeline. Corporate responsibility cannot really be met unless you have a collective effort and Regeneron has such a great commitment across all of our functions and all of our areas.

Beth: I feel like the experience of the last few years has really honed our skills and our ability to do that. So I'm really looking forward to seeing what the Regeneron community can do next.

Sally Paull, Senior Vice President, Human Resources: You've been here now for a little over a year, and you get the chance to really experience our culture in action. What's the culture?

Smita Pillai, Chief Diversity, Equity and Inclusion Officer: What got me really attracted to join this company was the core values that this company stands on: leading with science all the way to doing the right thing, and I see that every single day in every employee that I interact with.

Sally: I think over the last two years, we've hired, if you can believe this, almost 40% of our population, nearly 4,000 full-time employees. This year, we're going to grow maybe another thousand people, a lot of additional colleagues joining, to be sure. I think about how this actually creates an imperative for us to really show up and transmit these values. You spent your initial months out and about in the company, more than 3,000 people that you found the time and the opportunity to engage with, and the outcome of all of that was a framework, a strategic framework, to guide our diversity, equity, and inclusion efforts, but clearly linked to the Regeneron way.

Smita: It's a great question, which is why should Regeneron, a science company, care about DEI? When we designed the DEI vision, mission, and strategy for the company, it was inevitable that we had to link it to the core of who we are, which is science to medicine. The best and brightest ideas can come from anyone, from any background, and can we create a culture that really brings in the best ideas of people, leading to better science? Better workplace will lead to better science, which will inevitably lead to a better world.

Sally: What you've just expressed is that this is a business imperative. There's a huge element about our people and our employees, and that's critically important, but it's really the starting point.

Smita: We've had some tremendous progress in 2021 in terms of building relationships, establishing some key partnerships, and we've started seeing early results. 40% of the interns that we brought in were people of color in the United States, for example. More women have been brought into the workforce. As you know, 49% of our workforce is women globally.

Sally: Yes, this is great. What are you looking forward to this year?

Smita: With the foundation now solidly set, as I'm looking into 2022, I'm really looking towards scaling our efforts. Better workplace, which includes representation and culture, better science, how are we investing and improving in clinical trial diversity, health equity outcomes, genetic research and diversity there, in early research, therapeutic focus areas. And in the better world, are we putting money where our mouth is? How is our supply diversity going to improve and increase over the years? How are we investing in underrepresented communities from a STEM investment point of view, from an education point of view?

Sally: Diversity, equity, and inclusion is the cornerstone that allows us to deliver impeccable science and all the amazing medicines that we bring to patients.